Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

heptaplatin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms. Their clinical… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2016
Highly Cited
2016
The intermolecular forces between anti–cancer molecules such as Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, Lobaplation… 
  • figure 2
  • figure 1
Review
2013
Review
2013
Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of… 
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2010
Highly Cited
2010
Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian… 
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Review
2010
Review
2010
Cisplatin has become one of the most commonly used compounds for the treatment of a wide spectrum of human malignancies… 
2006
2006
Heptaplatin (HTP), a newly developed platinum analog, has been approved for the treatment of gastric cancers in South Korea. In… 
Review
2005
Review
2005
Research in the field of bioinorganic chemistry has been stimulated by the worldwide success of the anticancer drug cisplatin. 40… 
2004
2004
BackgroundHeptaplatin is a new platinum derivative with anticancer activity against various cancer cell lines, including… 
  • table 1
2004
2004
Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single… 
  • table 2
  • table 1
  • figure 1
  • table 3
2002
2002
HeadingAbstractPurpose. Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than… 
  • table 2
  • table 1
  • figure 2
  • figure 4
  • figure 3